کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5923154 | 1571164 | 2016 | 8 صفحه PDF | دانلود رایگان |

- SHR model showed correlation between hypertension and sleep-related movement disorders.
- Dopamine seems to be involved in the correlation of hypertension and sleep-related movement disorders.
- Physical exercise improved the hypertension and the sleep-related movement disorders symptoms.
- Enalapril improved the hypertension and the sleep-related movement disorders symptoms.
The relationship between hypertension and sleep-related movement disorders has been hypothesized for humans, but the causes and mechanisms have not been elucidated. We investigated whether an alteration in blood pressure (BP) induced by physical exercise and/or an angiotensin-converting enzyme inhibitor (enalapril) could affect locomotor activity in spontaneously hypertensive rats, with emphasis on the dopaminergic system. We used SHR and normotensive Wistar rats distributed into 4 groups for each strain: control, physical exercise, enalapril and physical exercise + enalapril. Physical exercise was performed on a treadmill, and enalapril was administered by gavage, both for 8 weeks. During this period, locomotor activity was evaluated in an open field test, and BP was evaluated by tail plethysmography. Dopaminergic receptors, dopamine transporter and tyrosine hydroxylase levels at the striatum were evaluated by Western blotting. The control group of spontaneously hypertensive rats showed higher BP, increased activity in the open field test and lower levels of D2 receptors and tyrosine hydroxylase compared with all other groups throughout the experimental period. In general, physical exercise and enalapril attenuated these alterations. This study suggested the existence of comorbidity between hypertension and sleep-related movement disorders in spontaneously hypertensive rats. Physical exercise and enalapril conferred protection for both hypertension and the observed behavioral changes. In addition, these treatments led to changes in dopaminergic signaling in the striatal region (i.e., D2 receptor, TH and DAT).
Journal: Physiology & Behavior - Volume 154, 1 February 2016, Pages 161-168